Today marks an amazing milestone for Atreo. I am excited to share closing of our 2nd fund raising round, providing the necessary capital to support our current and prospective clients and further advancements to our next generation RTSM platform. Thank you to all investors who took part in this round, many of whom chose to reinvest in Atreo based on our progress to date and confidence in our team.
To say I am proud of what we have accomplished over the past year is a huge understatement. We have been so fortunate to align with driven, inquisitive, and collaborative Atreo team members who share our values and vision for what can be accomplished by leveraging new technology with an open mind.
Atreo’s commercial launch has been overwhelmingly well received. Our initial client partners have recognized first-hand the many benefits of our approach, collaborative delivery, simplicity of our platform and the time saved in comparison to the industry norm. We are truly grateful for their enthusiasm to embrace an emerging technology company.
“Now that I have worked with Atreo, there is no reason to explore another RTSM provider.”
Atreo’s 1st Client | Head of Clinical Operations
Stay tuned for exciting updates in the weeks to come!
Our team would love the opportunity to learn about your RTSM goals, upcoming trials, and share more about Atreo's advantages. Please reach out to schedule an Atreo demo.